On paper, biosimilars have great potential to cut development costs, expand patient access to biologics, and improve affordability. The practical reality is that these goals are difficult to achieve.

Pharmacy benefit managers received substantial attention during 2024. Congress and regulating agencies including the FTC and HHS scrutinized PBM business practices and related profits. As a new ...

After inking and expanding a biosimilar production partnership with Pfizer this summer, Korea’s Samsung Biologics is boosting yet another Big Pharma manufacturing agreement. Monday, Samsung said it ...

Novartis may be in the process of spinning out its generics and biosimilar outfit, Sandoz, but that doesn't mean the latter company is pausing manufacturing investments. In fact, it's quite the ...

Formycon AG (FSE: FYB, Prime Standard, "Formycon") and OneSource Specialty Pharma Limited (BSE: 544292, NSE: ONESOURCE, ...

Biosimilars trade groups and manufacturers have expressed concern about what they say are “unnecessary hurdles” present in the US Food and Drug Administration’s (FDA) recent draft guidance on ...

In the United States, where around 8 million people rely on insulin for diabetes management, soaring prices have created barriers to accessibility. As Congress takes initial steps to cap monthly ...

A biosimilar drug manufacturer is concentrating on process optimization to increase uptake of its products in lower-income countries. According to Jeffrey Hausfeld, MD, chairman of the board of ...

The increasing demand from government agencies, insurers and patients to reduce the steep cost of blockbuster biopharmaceutical products has created considerable opportunities in the global biosimilar ...

Biopharmaceutical company Pangen, led by CEO Yoon Jae-seung, is developing three blockbuster-class biosimilars and plans to complete their production processes ...

Patent litigation reform could accelerate US biosimilar market entry, which lags behind the EU due to protracted legal processes. Biosimilar manufacturers face options like pre-clearance, "at-risk" ...

Providers and patients who want to understand biosimilars can now navigate through a new web app, that was created by Prime, and delivered in partnership with the AMCP Foundation and Biosimilars ...